Neuroblastoma
NB-1 A.Pession, A.Prete, et al.
Immunotherapy with low-dose recombinant interleukin-2 after high-Dose
chemotherapy and autologous stem cell transplantation in neuroblastoma.
British journal of Cancer(1998)
NB-2 Madeline Bauer, Gregory H.Reaman, et al.
A Phase 2 Trial of Human Recombinant Interleukin-2 Administered as a 4-Day
Continuous Infusion for Children with Refractory Neuroblastoma, Non-Hodgkin's
Lymphoma, Sarcoma, Renal Cell Carcinoma, and Malignant Melanoma
Cancer June15,1995,Vol.75,No.12
NB-3 R.Ladenstein, et al.
A Multicenter Observer-blind Randomized Phase 2 Parallel Study Comparing
Three Doses of Subcutaneous Interleukin-2 after Megatherapy and peripheral
Stem Cell Reinfusion in Stage 4 Neuroblastoma in patients over 1 year of age
Protocol. Feb. 1997
NB-4 Clinical Abstracts with IL-2 with Neuroblastoma
NB-5 V.Nève, A.B.M.Foot, J.Michon et al.
Longitudinal Clinical and Functional Pulmonary Follow-Up After
Megatherapy, Fractionated Total Body Irradiation, and Autologous Bone
Marrow Transplantation for Metastatic Neuroblastoma
Medical and Pediatric Oncology 32:170-176(1999)
Protocol Collection with IL-2
P-1 J.Atzpodien, H.Kirchner, et al.
Multicentre Randomised PhaseⅢStudy of Adjuvant Treatment of Renal Cell
Carcinoma with IL-2, IFN-α and 5-FU vs No Treatment
P-2 J.Atzpodien, H.krichner
Multicentre Out-patient Study for the Treatment of Advanced Renal Cell
Carcinoma with Il-2, IFN-α and 5-FU
(The Hannover Regimen)
P-3 European Organization for Research & Treatment of Cancer(EORTC)-
Genito-Urinary Tract Cancer Cooperative Group Adjuvant Interleukin-2,
Interferon-α and 5-FU for Patients with high Risk of Relapsed afer Surgical
Treatment for Renal Cell Carcinoma
P-4 W. Den Otter, A.Bugaiski, et al.
Protocol to Study Effect of Intravesical IL-2 on a Marker Lesion in Patients
with Category Ta/T2 Multiple Superficial Bladder Cancer. A Phase 2 Study
P-5 R.Ladenstein, J.Michon,et al.
A Multicenter Observer-Blind Randomised Phase 2 Study Comparing three
Doses of Subcutaneous IL-2 after Megatherapy and Peripheral Stem cell
Reinfusion in stage 4 Neuroblastoma in Patients over 1year of age.
(Final Protocol/Feb. 1997)
P-6 N.J.Lygidakis,
Multimodality Treatment Utilising Locoregional Immunostimulation and Locoregional
Chemoembolization in Patients with secondary Liver Tumors of Colorectal Origin
An I.G.S.C. Project
P-8 N.J.Lygidakis, P.Kosmidis, et al
Induced Targeting Locoregional in vivo Dual Immunostimulation for Patients
with Unresectable Pancreatic Carcinoma
P-9 B.L.Rapoport, et al.
Phase 2 Study of Biochemotherapy with Dacarbazine, Cisplatin, s.c. IFN-α and
s.c. IL-2 in the Treatment of Patients with Metastatic Malignant Melanoma
P-10 Wollerberg, Kastenbauer, J.Schaumberg
Gene Therapy-Phase I Trial for Primary untreated Head and Neck Squamous Cell
Cancer(HNSCC) UICC Stage 2-4 with a single Intratumoral Injection of IL-2
Plasmids Formulated in DoTMA/Chol
Human Gene Therapy 10: 141-147 (Jan 1, 1999)
P-11 F.Dazzi, EJ.Kanfer, et al.
Dual Immunotherapy with Donor Lymphocytes and Interleukin-2 for High-Risk
Relapsed Leukemia Following Allogenic Marrow Transplantation
P-12 J.Atzpodien, H.Kirchner
Protocol for the Management of Patients with Metastatic Renal Cell Carcinoma
P-13 H.Huland, E.Huland
Therapy of pulmonary MRCC(Inhalation of IL-2)
P-14 O.A.Brinkmann, et al.
Combined Radio-chemo-immunotherapy in renal cell carcinoma for soft tissue
& bone metases
P-15 Unresectable Non-small cell lung cancer: Clinical Efficacy on survival of
standard chemotherapy treatment vs standard chemotherapy plus lymphocyte
activation module with IL-2
P-16 J.Atzpodien, H. Kirchner.
The Management of Patients with Metastatic Renal Cell Carcinoma
P-17 J.Atzpodien, H.Kirchner, J.Anton et al.
Prospective Randomized Phase III Trial Concerning Adjuvant Therapy of Renal Cell
Carcinoma with IL-2, IFNa-2a & 5-FU in comparision with an untreated control group
(protocol)
P-18 L. Fumagalli, et al.
Multimodal Salvage Treatment with Locoregional IL-2 Immunotherapy in Unresectable
Primary Liver Cancer: A Phase I b Study
Basis for Study Protocol, April 2000
P-19 Chiron BV
Protocol to Study the Effect of Local Injections of Interleukin-2 in Unresetable Tumours in Liver.
A Phase II Study
P-20 Regimen for Neuroblastoma, Post PBSCT IL-2/13-CRA
Lymphomas
LM-1 MC Benyunes, C Higuchi, A York, et al.
Immunotherapy with interleukin-2 with or without lymphokine-activated
killer Cells after autologous bone marrow transplantation for malignant lymphoma :
A feasibility trial
Bone Marrow Transplantation.(1995)16. 283-288
LM-2 N.Vey, D.Blaise, P.Tiberghien, et al.
A Pilot Study of autologous Bone Marrow Transplantation Followed by
recombinant Interleukin-2 in Malignant Lymphomas
Leukemia and Lymphoma. Vol.21.pp.107-114
LM-3 D.Raspadori, F.Lauria, M.A.Ventura, et al.
Low doses of rIL-2 after autologous bone marrow transplantation induce a "prolonged"
immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas
Ann Hematol(1995)71:175-179
LM-4 F.Lauria, D.Raspadori, MA. Ventura, et al.
Immunologic and clinical modifications following low-dose subcutaneous
administration of rIL-2 in non-Hodgkin’s lymphoma patients after autologous
bone marrow transplantation
Bone Marrow Transplantation.(1996)18.79-85
LM-5 K.van Besien, K.Margolin, R.Champlin, et al.
Activity of Interleukin-2 in Non-Hodgkin’s Lymphoma following
transplantation of Interleukin-2-Activated autologous Bone Marrow or Stem Cells
The Cancer Journal from Scientific American
LM-6 Clinical Abstract
LM-7 J.Friedberg, D.Neuberg, et al.
Combination Immunotherapy with Rituximab and IL-2 in patients
with Relapsed or Refractomy follicular NHL
British Journal of Hematology (2002) 117:828-834
LM-8 Thomas L. Kiss, David Spaner, et al.
Complete remission of tumour with IL-2 therapy in a patient with non-Hodgkin's lymphoma
post allergic bone marrow transplant associated with polyclonal T-cell bone marrow lymphocytosis
British Journal of Haematology (2003), 120, 523-525
LM-9 Kim A. Margolin, Koen Van Besien, et al.
Interleukin-2-activated autologous bone marrow and peripheral blood stem cells
in the treatment of acute leukemia and lymphoma
Biology of Blood and Marrow Transplantation 5: 36-45 (1999)
LM-10 Christina Rogalski, Reinhard Dummer, et al.
Immunomodulators in the treatment of cutaneous lymphoma
JEADV 13(1999) 83-90
Oral Cancer
OC-1A De Stetani, G. Forni, et al.
Improved Survival with Perilymphatic IL-2 in Patients
with Resectable Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
Cancer July 1, 2002
OC-2B Wollenberg, Kastenbauer, et al.
Gene Therapy-Phase I Trial for Prmary Untreated Head and Neck Squamous Cell Cancer
UICC Stage II-IV with a Single Intratumoral Injection of hIL-2 Plasmides Formulated
in DOTMA/Chol
Human Gene Therapy 10:141-147 (Jan. 1, 1999)
Intrapleural Administration
IP-1 P. Astoul, D. Picat-Joossen, et al.
Intrapleural Administration of IL-2 for the Treatment of Patients with Malignant Pleural
Mesothelioma: A Phase II Study
Cancer, Nov 15, 1998, Vol.83, No.10
IP-2 Lucchi M, Chella A, Melfi F, Dini P, Tibaldi C, Fontanini G, Mussi A.
Four-modality therapy in malignant pleural mesothelioma: a phase II study.
J Thorac Oncol. 2007 Mar;2(3):237-42.
Lymphocytes
LC-1 Angelos E. Papatestas, Allan E. Kark
Peripheral Lymphocyte counts in breast cancer: An index of immune competence
Cancer 34:2014-2017, 1974
LC-2 K. Yamaguchi, S. Maeda, et al.
Prognostic Factors in colorectal carcinoma: Signigicance of peripheral T lymphocytes
Int Surg 1989; 74: 232-239
LC-3 L.A. Fumagalli, J. Vinke, et al.
Lymphocyte count as biomarker for patient outcome on subcutaneous interleukin-2 therapy
Proceedings of ASCO Volume 19 20; 1861 (Abstract)
LC-4 L Fumagalli, P Lissoni, et al.
Pretreatment serum markers and lymphocyte response to interleukin-2 therapy
British Journal of Cancer (1999) 80(3/4),407-411
LC-5 R.A.J. Janssen, D.Th. Sleijfer, et al.
Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response
in subcutaneously spplied rIL-2 therapy of renal cell carcinoma
British Journal of Cancer (1992), 66, 1177-1179
LC-6 Kenneth E. Stanley
Prognostic Factors for survival in patients with inoperable lung cancer
JNCI 65: 25-32, 1980
LC-7 Chiron Italy
Physiopathology of interleukin-2 in tumourous immunodeficit associated and clinical
correlations with lymphocyte count and survival
LC-8 Andre Bosly, Thierry Guillaume, et al.
Effects of escalating doses of recombinant human interleukin-2 in correcting functional
T-cell defects following autologous bone marrow transplantation for lymphomas and
solid tumors.
Exp. Hematol. 20:962-968 (1992)
Future Directions
FD-1 Michael T. Lotze
Future Directions for Recombinant Interleukin-2 in Cancer:
A Chronic Inflammatory Disorder
The Cancer Journal from Scientific America Vol 3. Suppl 1. 1997 (DEC)
FD-2 Kichael T.Lotze, Beth Hellerstedt, et al.
The Role of Interleukin-2, Interleukin-12, and dendritic cells in Cancer Therapy
The Cancer Journal from Scientific America Vol 3. Suppl 1. 1997 (DEC)
FD-3 Paolo Lissoni
Effects of Low-Dose Recombinant Interleukin-2 in Human Malignancies
The Cancer Journal from Scientific America Vol 3. Suppl 1. 1997 (DEC)
FD-4 Paul M.Sondel, Jacquelyn A.
Combination Therapy with Interleukin-2 and Antitumor Monoclonal Antibodies
The Cancer Journal from Scientific America Vol 3. Suppl 1. 1997 (DEC)
FD-5 Kendall A. Smith
Rational Interleukin-2 Therapy
The Cancer Journal from Scientific America Vol 3. Suppl 1. 1997 (DEC)
Others
O-1 Brendan D.Curti, Augusto C.Ochoa, et al.
Phase 1 Trial of Anti-CD3-Stimulated CD4+ T Cells, Infusional Interleukin-2,
and cyclophosphamide in Patients with Advanced Cancer
Journal of Clinical Oncology, Vol.16, No.8Aug,1998:pp2752-2760
O-2 Ralph S.Freedman, Renato Lenzi, et al.
Intraperitoneal immunotherapy of peritoneal carcinomatosis cytokines
Cellular & Molecular Therapy 1998. Vol.4.pp121-140
O-3 B.Wollenberg, Dr.Kastenbauer, et al.
Gene Therapy-Phase I Trial for Primary Untreated Head and Neck Squamous
Cell Cancer(HNSCC) UICC Stage Ⅱ-Ⅳ with a single Intratumoral Injection
of hIL-2 Plasmids Formulated in DOTMA/Chol
Human Gene Therapy 10:141-147(Jan 1, 1999)
O-4 IL-2 Toxicity management(Out patient Management Guidelines)
O-5 D.Sundin, M.Wolin
Toxicity by Management in Patients Receiving Low-dose Aldesleukin Therapy
The Annals of pharmacotherapy 1998. Vol.32
O-6 E.Galanis, J.Rubin, et al.
Immunotherapy of Advanced Malignancy by Direct Gene Transfer of an
Interleukin-2 DNA/DMRIE/DOPE Lipid Complex:phase 1/2 Experience
Journal of Clinical Oncology, vol 17, no10(Oct)1999:3313-3323
O-7 L.Rodella, L.Zamai, et al.
IL-2 & IL-15 differentially predispose NK-Cells to apoptosis mediated by endothelial
and tumour cells
British Jr of Hematology, 2001, 115, 442-450
O-8 R.Zarcone, P.Bellini, et al.
Combination Therapy with IL-2 & alpha-IFN for the treatment of patients
with cervical condilomatous
Minerva Ginecologica, 1996,48,111-113
O-9 E.C.Benton
Treatment of warts with Immune Response Modifiers
British Jr. of Dermatology, 143, 2000, 919-922
O-10 IL-2 Abstracts from Annual Meeting
ASCO, May 2002
O-11 P.Lissoni, S.Barni, et al.
Lower Survival in Metastatic Cancer Patients with Reduced IL-2 Blood Concentrations
with cervical condilomatous
Oncology 1991;48:125-127
O-12 S.Meijer, W.Urba, et al.
Adoptive Cellular Therapy with Tumor Vaccine Drainning Lymph Node Lymphocytes After
Vaccination with HLA-beta7/beta2-Micoroglobulin Gene-Modified Autologous Tumor Cells
Journal of Immunotherapy 25(4):359-372, 2002
O-13 P.Lissoni , M.Mandala, et al.
Progress Report on the Palliative Therapy of 100 patients with Neoplastic Effusion
by intracavity Low-Dose IL-2
Oncology 2001;60:308-312
O-14 P.Hwu, R.Freeman et al.
The Immunotherapy of Patients with Ovarian Cancer
Journal of Immunotherapy (2002), 25(3):189-201
O-15 Anton H.C, Jan-Willem Koten, et al.
The Mechanism of Regression of Solid SL2 Lymphosarcoma after IL-2 Therapy
Cancer Immunol Immunother (2002) 51;492-498
O-16 K.Cerea, F.Romano, L.Fumagali, et al.
Phase IB Study on Prevention of Surgery-Induced Immunodeficiency
with Preoperative Administration of Low-Dose S.C. IL-2 in Gastric Cancer Patients
Journal of Surgical Oncology 2001;78:32-37
O-17 IL-2 Abstracts from the 18th Annual Scientific Meeting of the Int'l Society for
Biological Therapy of Cancer, Oct-Nov. 2003
Journal of Immunotherapy, Vol.26, No.6, 323
O-18 IL-2 in adjuvant Therapy
O-19 Fumagalli L.A. et al.
Lymphocyte counts independently predict overall survival in advanced cancer patients:
a biometer for IL-2 therapy
Journal of Immunotherapy 26(5): 394-403, 2003
O-20 Carlo Marras, Camela Mendola, et al.
Immunotherapy and biological modifiers for the treatment of malignant brain tumors
Current Opinion in Oncology 2003, 15: 204-208
O-21 Tanya Repka, Elena G. Chiorean, et al.
Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study
Clinical Cancer Research, July 2003, Vol.19, 2440-2446
O-22 A. Schmittel, T. Proebstle, et al.
Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up
study in 94 stage IV melanoma patients
European Journal of Cancer 39 (2003) 476-480
O-23 Xin Han, George D. Wilbanks, et al
IL-2 enhances standard IFN-gamma/LPS activation of macrophage cytotoxicity
to human ovarian carcinoma in vitro: A potential for adoptive cellular immunotherapy
Gynecologic Oncology 75, 198-210 (1999)
O-24 Giovanni Mantovani, Antonio Maccio, et al.
Immunotherapy(recomninant interleukin-2), hormone therapy(medroxyprogesterone
acetate) and antioxidant agents as combined maintenance treatment of responders
to previous chemotherapy
Int J of Oncology 18: 383-391, 2001
O-25 Jens Atzpodien, Alfred Korfer, et al.
Home therapy with recombinant interleukin-2 and interferon-alpha2b in
advanced human malignancies
The Lancet, Junw 23, 1990, pp.1509-1512
O-26 A Nicolini, PA Mancini, et al.
Immunological and side effects of low sc recombinant interleukin-2 dose
in addition to conventional treatment in relapsed breast and colorectal
cancer patients
Biomed & Pharmacother 1996;50:344-349
O-27 Marco Maltoni, Marco Pirovano, et al.
Biological indices predictive of survival in 519 italian terminally III cancer patients
Journal of Pain and Symptom Management, Vol.13, No.1, January 1997
O-28 Yutaka Moriyama, Toshihiro Hashimoto, et al.
Angiosarcoma of vagina successfully treated with interleukin-2 therapy and
chemotherapy
J. Obstet. Gynaecol. Res. Vol.27, No.4: 231-235 2001
O-29 Kimberly R. Lindsey, Steven A. Rosenberg, et al.
Impact of the number of treatment courses on the clinical response of patients
who receive high-dose bolus interleukin-2
Journal of Clinical Oncology, Vol.18, No.9 (May), 2000: pp 1954-1959
O-30 J.A. Sosman, P. Stiff, et al.
Pivot trial of interleukin-2 with granulocyte colony stimulating factor for the
mobilization of progenitor cells in advanced breast cancer patients undergoing
high-dose chemotherapy: expansion of immune effector within the stem cell
graft and post-stem-cell infusion
Journal of Clinical Oncology, Vol.19, No3 (February 1), 2001: pp634-644
O-31 G. Difelice, L. Fumagalli, et al.
Reactivation of a normal endogenous secretion of interleuki-2 in metastatic
cancer patients by a chronic subcutaneous injection of interleukin-2
Journal of Biological Regulators and Homeostatic Agents Vol.10, No.4, pp.98-99
O-32 Z Krastev, V Koltchakov, et al.
Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2
Hepato-Gastroenterology 50 (2003) 1006-1016
O-33 Jon M Wigginton, Robert H Wiltrout
IL-12/IL-2 combination cytokine therapy for solid tumors: translation from
bench to bedside
Expert Opin Biol Ther (2002) 2(5):513-524
O-34 Mark Middleton, Mark Sarno, et al.
Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer
patients: implications for combined immunotherapy with interleukin-2
J Clin Pharmacol 2002;42:774-781
O-35 Hiroki Yamaue, Hiroshi Tanimura, et al.
Multidisciplinary treatment for gastric cancer patients by chemoimmunotherapy
Hepato-Gastroenterology 1999; 46: 620-625
O-36 Young-Ik Son, Robbie B. Mailliard, et al.
Dendritic cells pulsed with apoptotic squamous cell carcinoma have anti-tumor
effects when combined with interleukin-2
Laryngoscope 111: August 2001; 1472-1478
O-37 Gwenaelle Gravis, Mireille, et al.
Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft
tissue sarcoma patients. Results of a prospective phase II clinical trial
Eur. Cytokine Netw., Vol.12, No.2, June 2001, 239-243
O-38 Kwan-Hwa Chi, Jeffrey N. Myers, et al.
Phase II trial of systemic recombinant interleukin-2 in the treatment of
refractory nasopharyngeal carcinoma
Oncology 2001; 60: 110-115
O-39 Charlotte Cunningham-Rundles, Carol Bodian, et al.
Long-term low-dose IL-2 enahnced immune function in common variable
immunodeficiency
Clinical Immunology, Vol.100, No.2, August, pp.181-190, 2001
O-40 Robert O. Dillman, Curtis Church, et al.
Long-term survival after continous infusion interleukin-2
Cancer Biotherapy & Radiopharmaceuticals Vol.12, No.4, 1997, 243-248
O-41 Giuseppe Sconocchia, Nella Y. Cococcetta, et al.
Subcutaneous administration of interleukin-2 triggers Fcr receptor I expression
on humanperipheral blood neutrophils in solid and hematologic malignancies
Journal of Immunotherapy 24(4): 374-383, 2001
O-42 Jungeun Lee, Bruce M. Fenton, et al.
Interleukin-2 expression by tumor cells alters both the immune response and the
tumor microenvironment
Cancer Research 58, 1478-1485, April 1, 1998
O-43 Abstracts
17th Annual Scientific Meeting of the Society for Biological Therapy, La Jolla
November 7-10, 2002
J. Immunother., Vol.25, No.6, 2002
O-46 Adrea Nicolini, Angelo Carpri, and Giuseppe Rossi
An Immunotherapy Schedule in Endocrine-Dependent Metstastic Breast Cancer
Correlation Between Clinical Course and Immunologic Parameters
J Immunother, Vol.28, No.3, May/June 2005
O-47 G. Gravis, P. Viens, et al.
rIL-2 in metastatic soft tissue sarcomas refractory to chemotherapy: response
and enhancement of further chemosensity
Anticancer Research 18: 3699-3704(1998)
O-48 IL-2 Inhalation Nebulizer
O-49 John W. Eklund and Timothy M. Kuzel
A review of recent findings involving interleukin-2-based cancer therapy
Curr. Opin. Oncol. 16: 542-546, 2004
O-50 W. Schwinger, V. Klass, et al.
Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patietns
Annals of Oncology 16: 1199-1206, 2005
O-51 정원석, 박경기, 김영식, 이석영, 고우진
인터루킨-2를 사용한 요도 내 첨규 콘딜로마 치료
( Treatment of Urethral Condyloma by Interleukin-2 )
대한비뇨기과학회지, 제49권, 제7호, 2008년 7월
istered as a 4-Day
ma, Non-Hodgkin's
lation and Locoregional
of Colorectal Origin
atin, s.c. IFN-α and
Neck Squamous Cell
nal Cell Carcinoma
oma for soft tissue
Therapy of Renal Cell
an untreated control group
notherapy in Unresectable
-2 in Unresetable Tumours in Liver.
malignant lymphoma :
tation induce a "prolonged"
Hodgkin's lymphomas
after autologous
Marrow or Stem Cells
with non-Hodgkin's lymphoma
onal T-cell bone marrow lymphocytosis
eral blood stem cells
Neck Squamous Cell Cancer
2 Plasmides Formulated
nts with Malignant Pleural
immune competence
peripheral T lymphocytes
cutaneous interleukin-2 therapy
terleukin-2 therapy
therapy correlate with response
t associated and clinical
n-2 in correcting functional
ation for lymphomas and
in Cancer Therapy
mediated by endothelial
L-2 Blood Concentrations
mph Node Lymphocytes After
dified Autologous Tumor Cells
h Neoplastic Effusion
a after IL-2 Therapy
Gastric Cancer Patients
advanced cancer patients:
f malignant brain tumors
breast cancer: a pilot study
ha-2a therapy: a follow-up
rophage cytotoxicity
e cellular immunotherapy
y(medroxyprogesterone
reatment of responders
lly III cancer patients
sponse of patients
ol.10, No.4, pp.98-99
treated with interleukin-2
unteers and cancer
moimmunotherapy
ma have anti-tumor
ne response and the
astic Breast Cancer
ediatric cancer patietns